Consistent with studies demonstrating that STAT3 is an early diagnostic tumor marker that is often constitutively overexpressed and activated in breast cancer, strategies aimed at modulating Ca2+ signaling in these tumors may be useful as a novel therapeutic approach. This evidence concerns the gene STAT3 and breast carcinoma.